Related Experiment Video
Updated: Sep 21, 2025
Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes
Published on: May 5, 2020
Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cells
Jiangtao Li1, Xin Feng1, Xiang Wei2
1Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.
Insights
Induced pluripotent stem cells (iPSCs) offer a way to study hypertrophic cardiomyopathy (HCM) by creating patient-specific heart cells (iPSC-CMs). These models are advancing our understanding of HCM and aiding drug development.
Area of Science:
- Cardiovascular Research
- Stem Cell Biology
- Genetics
Background:
- Studying hypertrophic cardiomyopathy (HCM) pathogenesis is challenging due to limited early-stage myocardial tissue.
- Induced pluripotent stem cells (iPSCs) provide a solution by enabling in vitro differentiation into patient-derived cardiomyocytes (iPSC-CMs).
Purpose of the Study:
- To review current approaches for establishing iPSC models for HCM research.
- To summarize the application of genome editing techniques in iPSC-based HCM models.
- To discuss methods for maturing iPSC-CMs and their application in studying HCM.
Main Methods:
- Establishment of patient-derived iPSC lines.
- Differentiation of iPSCs into cardiomyocytes (iPSC-CMs).
- Application of genome editing techniques.
- Maturation strategies for iPSC-CMs (e.g., prolonged culture, mechanical/electrical stimulation).
- Assessment of cellular morphology, contractility, electrophysiology, calcium handling, mitochondrial function, and metabolism.
Main Results:
- Numerous iPSC-CM models of HCM have been established globally.
- Diverse measurement techniques are employed to characterize these models.
- Preliminary findings suggest iPSC-CMs provide valuable insights into HCM pathogenesis.
- These models show promise for drug development and safety testing.
Conclusions:
- iPSC-CMs represent a powerful tool for investigating hypertrophic cardiomyopathy.
- Despite immaturity, iPSC-CMs offer significant insights into disease mechanisms.
- This technology facilitates drug discovery and safety evaluation for HCM treatments.
Abstract:
One of the obstacles in studying the pathogenesis of hypertrophic cardiomyopathy (HCM) is the poor availability of myocardial tissue samples at the early stages of disease development. This has been addressed by the advent of induced pluripotent stem cells (iPSCs), which allow us to differentiate patient-derived iPSCs into cardiomyocytes (iPSC-CMs) in vitro. In this review, we summarize different approaches to establishing iPSC models and the application of genome editing techniques in iPSC. Because iPSC-CMs cultured at the present stage are immature in structure and function, researchers have attempted several methods to mature iPSC-CMs, such as prolonged culture duration, and mechanical and electrical stimulation. Currently, many researchers have established iPSC-CM models of HCM and employed diverse methods for performing measurements of cellular morphology, contractility, electrophysiological property, calcium handling, mitochondrial function, and metabolism. Here, we review published results in humans to date within the growing field of iPSC-CM models of HCM. Although there is no unified consensus, preliminary results suggest that this approach to modeling disease would provide important insights into our understanding of HCM pathogenesis and facilitate drug development and safety testing.
More Related Videos
08:37Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.
Published on: March 3, 2021
13:18Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
Published on: June 28, 2013
